AzurRx BioPharma: Phase II OPTION study of MS1819-SD progressing as planned
"AzurRx continues to make great strides in our clinical programs," said Thijs Spoor, the CEO of AzurRx. "Our current Phase II OPTION Study of MS1819-SD is progressing as planned, we have not seen any serious adverse events and the withdrawal rates have been low, which is compatible with, or below, other trials of synthetic enzymes. We remain on track to announce final data analysis of the OPTION Study in September 2019. Last month, we announced that we initiated a Phase 2 clinical trial to investigate MS1819-SD in combination with PERT, the existing standard of care for treating severe EPI in CF patients. That trial will focus on the clinical needs of the third of patients whose nutritional requirements cannot be met with PERT alone and we expect to announce preliminary data in early 2020. Our goal is to address the needs of CF patients by exploring the efficacy of both MS1819-SD replacement and combination therapies."